You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T/NK-cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022

CLL, SLL, HCL Trial in Dresden

Recruiting
  • CLL
  • +7 more
    • Dresden, Sachsen, Germany
      BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
    Apr 29, 2022

    Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

    Completed
    • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
    • +7 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 6, 2022

    Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

    Not yet recruiting
    • Adult T-cell Leukemia/Lymphoma
    • +4 more
    • CC-486 (5-azacitidine)
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 17, 2022

    NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

    Not yet recruiting
    • NK/T Cell Lymphoma Nos
    • Brentuximab Vedotin in Combination with Tislelizumab
    • (no location specified)
    Apr 6, 2022

    T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

    Recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • +3 more
    • Universal CD7-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 17, 2023

    Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

    Recruiting
    • Extranodal NK/T-cell Lymphoma
    • VT-EBV-N
    • Placebo
    • Busan, Korea, Republic of
    • +7 more
    Apr 28, 2022

    Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

    Not yet recruiting
    • Extranodal Natural Killer/T-cell Lymphoma
    • circulate free methylated EBV DNA
    • Nanjing, China
      The First Affiliated Hospital of Nanjing Medical University
    Apr 19, 2022

    Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +14 more
    • Cholecalciferol
    • Laboratory Biomarker Analysis
    • Scottsdale, Arizona
    • +4 more
    Jan 16, 2023

    Immunity, Innate, Colorectal Cancer Trial in Montreal (IVDD for NK cell activity in whole blood)

    Terminated
    • Immunity, Innate
    • Colorectal Cancer
    • IVDD for NK cell activity in whole blood
    • Montreal, Quebec, Canada
    • +2 more
    Jan 30, 2023

    T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

    Recruiting
    • T-cell Lymphomas
    • NK-Cell Lymphomas
    • Miami, Florida
    • +8 more
    Aug 1, 2022

    Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

    Recruiting
    • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
    • +2 more
    • Anti-PD-1 monoclonal antibody
    • +4 more
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Feb 23, 2022

    Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

    Recruiting
    • Anaplastic Large Cell Lymphoma
    • +19 more
    • Duarte, California
    • +2 more
    Aug 15, 2022

    T-cell Leukemia, T-cell Lymphoma Trial in ChongQing (CD7 UCAR-T cells, Fludarabine, Cytoxan)

    Recruiting
    • T-cell Leukemia
    • T-cell Lymphoma
    • CD7 UCAR-T cells
    • +3 more
    • ChongQing, Chongqing, China
      Department of Hematology, Xinqiao Hospital
    Jun 21, 2021

    LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive

    Recruiting
    • LGLL - Large Granular Lymphocytic Leukemia
    • +13 more
    • Duarte, California
    • +9 more
    Aug 9, 2022

    NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

    Not yet recruiting
    • NHL, Relapsed, Adult
    • +3 more
    • KUR-502
    • (no location specified)
    Aug 2, 2022

    Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

    Active, not recruiting
    • Anaplastic Large Cell Lymphoma
    • +4 more
    • Duarte, California
    • +3 more
    Jul 21, 2022

    Lymphoma Trial in United States (Ruxolitinib)

    Recruiting
    • Lymphoma
    • Miami, Florida
    • +9 more
    Oct 5, 2022

    Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell

    Active, not recruiting
    • Anaplastic Large Cell Lymphoma
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
    • +1 more
    Jul 26, 2022

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)

    Available
    • Extranodal NK/T-cell Lymphoma
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Mar 18, 2022

    Advanced Solid Tumors Trial in Wuxi (Anti-CAR-NK Cells)

    Recruiting
    • Advanced Solid Tumors
    • Anti-CAR-NK Cells
    • Wuxi, Jiangsu, China
      Wuxi People's Hospital
    Jan 18, 2022

    Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

    Recruiting
    • Early-stage
    • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
    • Anti-PD-1 monoclonal antibody
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Dec 7, 2021

    T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma Trial run

    Completed
    Has Results
    • T-Cell Peripheral Lymphoma
    • +3 more
    • Rituximab
    • +6 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Oct 28, 2021